Menopause study maps abrupt laboratory changes, with interpretation disputed

A study published October 12 in Nature Medicine reports that multiple laboratory measures change sharply around the final menstrual period, suggesting that reproductive aging has a distinct signature across the body. The findings could help researchers separate menopause-related changes from chronological aging, although independent specialists have challenged the authors’ description of a physiological “cliff.”

The investigation concerns the timing of measurable biological changes. It does not establish that every woman experiences sudden deterioration, or that changing these laboratory values would prevent disease. That distinction matters as the findings enter a broader debate about menopause and healthy aging.

Reconstructing a transition

Researchers analyzed US National Health and Nutrition Examination Survey data and records from Israeli health insurer Clalit. Their computational method reconstructs trajectories relative to the final menstrual period, accounting for variation in the age when menopause occurs. Most of the underlying analysis compares observations across people rather than following each participant through the entire transition.

The paper’s authors acknowledge that this reconstruction cannot replace detailed prospective tracking. Its timing estimates depend on assumptions about the distribution of menopause ages, and self-reported information introduces uncertainty.

According to Nature Portfolio’s accompanying research summary, the datasets encompassed more than 300 million laboratory tests from over one million women. In the US dataset, 52 of 90 tests showed statistically significant abrupt changes. These included measures related to reproductive hormones, bone metabolism, liver and kidney function, blood chemistry and lipids.

The summary also describes hormonal changes beginning well before the final period: anti-Müllerian hormone and estradiol declined more rapidly approximately 15 and 12 years beforehand, respectively, while follicle-stimulating hormone increased more rapidly around 14 years beforehand. Comparable abrupt patterns were not observed in men.

Why the language is contested

In reporting published October 13, ABC News described objections from Australian menopause specialists. Martha Hickey, who was not involved in the study, questioned the “cliff” terminology and warned that it could unnecessarily alarm women. Elina Safro also expressed skepticism about the interpretation.

Their criticism concerns how much a retrospective reconstruction can establish about the experience of individual women. Earlier prospective research, including the Study of Women’s Health Across the Nation, followed participants through menopause and described changes occurring over several years.

Study leader Uri Alon defended the analysis to ABC, citing comparisons with men, simulations and experimental data. These competing interpretations leave a concrete research question: whether repeated measurements in well-characterized individuals reproduce the sharp timing inferred from population records.

Hormone associations leave treatment questions open

Women using menopausal hormone therapy showed smaller changes in many laboratory measures, particularly those related to bone, liver and kidney function. That observation is potentially informative, but treatment was not randomly assigned.

The authors acknowledge that differences between hormone users and nonusers could remain despite statistical adjustment. Access to care and underlying health can influence who receives treatment, complicating causal interpretation. They say prospective randomized trials are needed to test treatment effects.

For healthspan research, the study offers a framework for investigating when different biological systems change around menopause. A population trajectory, however, is not an individual prognosis. Likewise, a laboratory difference is not interchangeable with fewer fractures, fewer cardiovascular events or more years of independent life. Establishing those benefits requires studies designed to measure them.